FitLife Brands Inc

Análisis de la acción FitLife Brands Inc (FTLF)

$8.000

-0.176 (-2.20%)Al cierre

Loading chart…
Máximo
8.120
Apertura
8.120
Precio medio ponderado por volumen
8.04
Volumen
6.95K
Capitalización
151.74M
Mínimo
8.000
Importe
55.85K
EV/EBITDA, TTM
7.55

FitLife Brands, Inc. is a developer and marketer proprietary nutritional supplements and wellness products for health-conscious consumers. It markets approximately 250 different products primarily online, through domestic and international GNC franchise locations as well as through various retail locations. It offers NDS Nutrition, PMD Sports, SirenLabs, Core Active, Nutrology, and Metis Nutrition (together, NDS Products); iSatori, BioGenetic Laboratories, and Energize (together, the iSatori Products); Dr. Tobias, All Natural Advice, and Maritime Naturals (together, the MRC Products) and MusclePharm. Its NDS brand includes premium weight loss, sports nutrition, and general health products. Its PMD brand includes premium sports nutrition products. Its Nutrology brand included sports nutrition and general wellness products with an emphasis on natural, vegan, and organic ingredients. Its SirenLabs brand includes weight loss and sports nutrition products.

fitlifebrands.com

Análisis de IA of FitLife Brands Inc (FTLF)

Mantener

Currently, FitLife Brands Inc (FTLF) is not a strong buy due to its low RSI of 37.37, indicating potential oversold conditions, and a significant year-to-date decline of 49.05%. Although there was a recent revenue growth of 65% year-over-year in Q2 2026, the company's gross margin has declined to 36.01%. The upcoming earnings report on November 16, 2026, could provide more clarity, but the current price of $8.03 and the forward P/E of 6.11 suggest caution as the stock is still underperforming.

Métricas de valoración

El PER previsto actual de FitLife Brands Inc (FTLF) es 6.26, frente a su media de 5 años de 7.67.

PER previsto

Valor razonable
Media 5A P/E
7.67
P/E actual
6.26
Sobrevalorada
14.10
Infravalorada
1.24

EV/EBITDA previsto

Valor razonable
Media 5A EV/EBITDA
5.63
EV/EBITDA actual
7.55
Sobrevalorada
10.22
Infravalorada
1.04

Precio/ventas previsto

Valor razonable
Media 5A P/S
0.93
P/S actual
0.68
Sobrevalorada
1.78
Infravalorada
0.09

Cronología de eventos

2026-04-01 (ET)

16:30:00

Major Averages Close Broadly Higher as Market Sentiment Improves

12:20:00

Major Averages Broadly Higher as Market Sentiment Improves

07:10:00

Legacy FitLife Reports Q4 Revenue of $25.9M

2025-11-13 (ET)

07:36:28

FitLife Brands Announces Q3 EPS of 9 Cents Compared to 21 Cents Last Year

2025-08-14 (ET)

07:03:17

FitLife Brands reports Q2 EPS 18c vs. 27c last year

Noticias

Preguntas frecuentes sobre FTLF, respondidas por Alphio AI

FitLife Brands, Inc. is a developer and marketer proprietary nutritional supplements and wellness products for health-conscious consumers. It markets approximately 250 different products primarily online, through domestic and international GNC franchise locations as well as through various retail locations. It offers NDS Nutrition, PMD Sports, SirenLabs, Core Active, Nutrology, and Metis Nutrition (together, NDS Products); iSatori, BioGenetic Laboratories, and Energize (together, the iSatori Products); Dr. Tobias, All Natural Advice, and Maritime Naturals (together, the MRC Products) and MusclePharm. Its NDS brand includes premium weight loss, sports nutrition, and general health products. Its PMD brand includes premium sports nutrition products. Its Nutrology brand included sports nutrition and general wellness products with an emphasis on natural, vegan, and organic ingredients. Its SirenLabs brand includes weight loss and sports nutrition products. It operates in the Consumer Non-Cyclicals sector (MEDICINAL CHEMICALS & BOTANICAL PRODUCTS industry).

Currently, FitLife Brands Inc (FTLF) is not a strong buy due to its low RSI of 37.37, indicating potential oversold conditions, and a significant year-to-date decline of 49.05%. Although there was a recent revenue growth of 65% year-over-year in Q2 2026, the company's gross margin has declined to 36.01%. The upcoming earnings report on November 16, 2026, could provide more clarity, but the current price of $8.03 and the forward P/E of 6.11 suggest caution as the stock is still underperforming.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Artículos relacionados

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar